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T THE November 1970 meeting of the American Philosophical
Society, Jonathan Rhoads organized and chaired a session on
transplantation that consisted of five formal papers (1–5). By
the time of this meeting, kidney, liver, heart, and pancreas transplanta-
tion already had been accomplished in humans and the first successful
bone marrow transplantations had been recorded (Table 1) (6–10).
But the results with these procedures were not yet good enough to gen-
erate much enthusiasm.
Moreover, it was not clear how to make things better. One reason
was that workers in the burgeoning special field of transplantation
immunology already had been disoriented by a conceptual error. As
early as 1962, the mistaken conclusion had been reached “by consen-
sus” that the engraftment of organs involved mechanisms fundamen-
tally different from those of successful bone marrow transplantation.
Although the error was a seemingly innocuous one, it became the basis
of a false paradigm that precluded the orderly development of trans-
plantation immunology, and limited progress in clinical transplantation
almost exclusively to the development of more potent antirejection drugs.
 
The Seed Planted by Medawar
 
How the invalid premise took root can be best understood from a his-
torical perspective. The chain of events began during the Battle of Brit-
ain, when Peter Medawar, a twenty-four-year-old Oxford zoologist,
was assigned to duty with the Scottish plastic surgeon Thomas Gibson.
The objective of the two men was to determine if skin removed from
recently dead persons could be used to surgically replace the burned
skin of fire bomb victims.
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Their studies provided evidence that rejection of the skin is an
immune reaction (11, 12). The key observation came from experiments
in which skin was repetitively transplanted from a specific donor to a
given recipient, placing each graft after the preceding one had been
rejected. The survival time of the skin was progressively shortened. For
example, the time to rejection might be ten days for a first graft, five
days for the next one, and only a few hours after four or five preceding
grafts (Fig. 1).
This kind of immunity (subsequently termed adaptive immunity)
resembles that mounted in response to infections such as tuberculosis,
in which the invading microorganism can exist within host cells with-
out killing them. It was later learned that adaptive immunity is depen-
dent on white cells (leukocytes) that are generated in the bone marrow,
and migrate through the blood to multiple destinations. The principal
 
Table 
 
1. Historical firsts: patient and allograft survival exceeding one year
 
Organ Ref City Date of TX Physician/Surgeon
 
Kidney 6 Boston 1/24/59 Murray
Liver 7 Denver 7/23/67 Starzl
Heart 8 Cape Town 1/2/68 Barnard
Bone marrow 9 Minneapolis 8/24/68 Good
 
Pancreas*
 
10
 
Minneapolis
 
6/3/69
 
Lillehei
 
* Simultaneous kidney and pancreas allografts in patient who had diabetes-associated renal failure.
TX 
 

 
 transplantation.
Figure 1. Peter Medawar’s experiment showing that when skin from the same
donor is repetitively transplanted to a given recipient, graft survival becomes
progressively shorter. This was convincing evidence that graft rejection is an
immune response.
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leukocyte reservoirs are the bone marrow, spleen, and lymph nodes
(and in lower mammals, the thymus gland). However, significant num-
bers of white cells of bone marrow origin also are part of the structure
of all tissues and organs. These cells, often referred to as “passenger
leukocytes,” are depicted symbolically in Figure 2 (left) by a bone sil-
houette within a kidney.
Very little of the foregoing information was known in the 1940s. In
fact, it was not demonstrated until the late 1950s that the key leuko-
cyte of the adaptive immune response is a white cell known as a lym-
phocyte. Nevertheless, Medawar’s demonstration that rejection is an
immune response, and the recognition in the 1950s that the response
is mounted by rapidly multiplying antigen-specific immune competent
leukocytes (Fig. 3, top), prompted many experimental attempts to
weaken the host versus graft immune reaction. This was done most fre-
quently by administering total body irradiation before or after skin or
organ transplantation. As late as 1960, however, these efforts had not
produced a single example in animals of a long-surviving organ recipient.
 
Billingham, Brent, and Medawar
 
The only potential ray of hope for clinical transplantation was con-
tained in a three and a half page report published in the 3 October
1953 issue of the journal 
 
Nature
 
 (13). The first author was Rupert
Figure 2. Part of the structure of all tissues and organs consists of white cells of
bone marrow origin that are often referred to as passenger leukocytes. Left: these
leukocytes are symbolized by a bone silhouette within a kidney. Right: after
transplantation, these donor leukocytes disappear from a successfully engrafted
organ and are replaced by similar recipient white cells.
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Figure 3. The historical view of the immune response induced by transplan-
tation. Top: a unidirectional host versus graft response, here against a kidney on
the left or above it a skin graft. Bottom: a mirror image of the top panel
following bone marrow cell engraftment. Here, the recipient was rejected by an
ostensibly unidirectional graft versus host response as the graft cells completely
replaced the recipient immune system. The revised current concept is shown in
Figure 14.
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Billingham, one of the speakers at the Rhoads symposium of 1970.
The other two were Leslie Brent and the team leader, the wartime
investigator, Peter Medawar, who by now had reached the ripe old age
of thirty-four. The trio soon would become known as the “holy trin-
ity” of transplantation immunology.
What they had done was to inject leukocytes that had been isolated
from the spleen or bone marrow of adult mice into the blood stream of
newborn mouse recipients (Fig. 4, top). Because the immune system
of the newborn mice was not yet developed enough to reject the donor
leukocytes, these donor cells proliferated and appeared to have re-
placed the recipient immune cells (Fig. 4, bottom). This condition is
known as 
 
complete donor leukocyte chimerism.
 
By 1955, comparable donor leukocyte chimerism was produced in
adult mouse recipients whose immunity had been weakened by total
Figure 4. The mouse models of acquired tolerance described between 1953
and 1956. White cells (leukocytes) were isolated from the spleen or bone marrow
of adult donor mice (upper left), and injected into the bloodstream of newborn
mice (upper right), or of irradiated adult mice (mid-right). Under both circum-
stances, the recipient immune system was too weak to reject the foreign cells (dark
shaded). With engraftment of the injected cells (i.e., donor leukocyte chimerism),
the recipient mice now could freely accept tissues and organs from the leukocyte
donor, but from no other donor (bottom left). Clinicians interested in organ trans-
plantation promptly envisioned the use of bone marrow cell transplantation as a
preparatory step to organ transplantation (see text).
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body irradiation (Fig. 4). Both the newborn and the irradiated adult
chimeric recipients now could accept skin or other tissues from the
original leukocyte donor, but from no other donor. These were the first
examples of acquired donor-specific transplantation tolerance (Fig. 4).
The next step appeared to be obvious: i.e., the engraftment of bone
marrow cells from the donor before or at the same time as organ trans-
plantation. These plans ground to an abrupt halt when Medawar’s
associates, Billingham and Brent, discovered that the engrafted donor
immune cells could turn the tables and reject the mouse recipients (14).
In this truly horrible complication, called graft versus host disease, the
recipient was eaten alive by the engrafted donor cells (Fig. 5). The “out
of control” graft versus host response came to be widely viewed as a
unidirectional immune reaction (Fig. 3, bottom) that was in essence
a mirror image of the ostensibly one-way host versus graft reaction re-
sponsible for tissue and organ rejection (Fig. 3, top).
 
Human Bone Marrow Transplantation: 1968
 
Graft versus host disease was found to be avoidable in mice if the
donor and recipient had a good tissue match. This condition could be
met in inbred rodent models by using donors and recipients of selected
strains. Clinical bone marrow transplantation was forestalled, how-
ever, until enough human tissue antigens were identified to permit the
obligatory matching (Fig. 6, right) (9). By this time (1968), bone marrow
cell engraftment was no longer a means to the end of organ transplanta-
tion. Instead, it became the definitive treatment for immune deficiency
diseases, blood disorders, and numerous other indications.
Figure 5. Lethal graft versus host disease in which the engrafted immune cells
of the donor attack and destroy the skin, lungs, intestine, liver, and other recipient
tissues and organs. This complication in a recipient whose immune system is
excessively weakened can be avoided only by donor-recipient tissue matching.
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The Empirical Development of Kidney
Transplantation: 1959 – 62
 
The escalation of mouse research to human application (Fig. 6, right)
was heralded as a prime example of “bench to bedside” research. In
contrast, kidney engraftment was accomplished first in humans rather
than in animals (Fig. 6, left). Defined as patient and graft survival of at
least one year, successes were recorded between January 1959 and the
end of 1962 in the seven kidney recipients summarized in Table 2.
The first six patients were preconditioned with the irradiation
strategy that had 
 
never
 
 worked in animals. The seventh was treated
instead with daily post-transplant doses of an experimental drug called
azathioprine (better known as Imuran
 
®
 
). The pathfinding first and
seventh recipients were patients of Joseph Murray at the Peter Bent
Brigham Hospital in Boston (6, 17), while the intervening five were
treated at separate (competing) Paris hospitals (Table 2) (15, 16).
 
The Epistemologic Collapse
 
Although kidney transplant successes constituted a “breakthrough,”
the results were utterly inexplicable. They had been achieved without
Figure 6. The divergence of the ostensibly unrelated fields of organ (left) and
bone marrow transplantation. The conclusion that the two kinds of transplanta-
tion involved different mechanisms of engraftment was the basis for an epistemo-
logic collapse in transplantation immunology (see text).
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tissue matching, and with no hint of graft versus host disease (Fig. 6,
left). Because none of the patients had been given a bone marrow cell
infusion, it was universally concluded that organ engraftment involved
mechanisms other than the donor leukocyte chimerism-associated ones
of acquired tolerance. In effect, this assumption detached organ trans-
plantation from the scientific base that had been established by the
mouse tolerance discoveries of Billingham, Brent, and Medawar. With
the agreement of both Murray (18) and Medawar (19), the consensus
conclusion hardened into dogma and was not challenged for the next
three decades.
Medawar remained puzzled by the success of organ transplanta-
tion for the rest of his life. Commenting on the search for unique mech-
anisms of organ engraftment and for strategies of “immunoregulation”
with which to acquire tolerance, he concluded that “the spectacle of a
scientist locked in combat with the forces of ignorance is not an inspir-
ing one if, in the outcome, the scientist is routed” (20). In fact, the
search for mechanisms of engraftment that were not associated with
donor leukocyte chimerism lasted for forty years, and still goes on in
many, if not most, transplant immunology laboratories.
 
Kidney Induced Tolerance?
 
Although the seven kidney cases that led to the divorce of organ and
bone marrow transplantation were viewed as a collective triumph, they
were, in fact, isolated exceptions to the usual outcome of failure. Two
further findings in 1962 and 1963 in Denver now allowed kidney
transplantation to be elevated from an uncertain experiment to a semi-
reproducible, albeit still flawed, clinical service (21). These observations
also marked the beginning of a trail that eventually would come back
full cycle to the holy trinity of Billingham, Brent, and Medawar.
 
Table 
 
2. Kidney transplantation 
 

 
6 months survival as of March 1963
 
Patient City (Ref) Date Donor Survival (mos.)
 
1 Boston (6) 1/24/59 Fraternal twin
 

 
50
2 Paris (15) 6/29/59 Fraternal twin
 

 
45
3 Paris (16) 6/22/60 Unrelated 18 (Died)
4 Paris (15) 12/19/60 Mother
 

 
12 (Died)
5 Paris (16) 3/12/61 Unrelated 18 (Died)
6 Paris (15) 2/12/62 Cousin
 

 
13
 
7
 
Boston (17)
 
4/5/62
 
Unrelated
 
11
 
Boston: Joseph E. Murray (patients 1 and 7).
Paris: Jean Hamburger (patients 2, 4, and 6), R. Küss (patients 3 and 5).
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The first finding was that kidney graft rejection that occurred
despite treatment with azathioprine could be readily reversed with
large doses of adrenal cortical steroids, contravening the previous view
that this immune response was one of biology’s most inexorable reac-
tions. The second observation was that organ grafts could self-induce
tolerance. Tolerance was inferred from the rapid decline in many
patients of the amount of treatment required at the outset to prevent or
control rejection (Fig. 7). Such kidney recipients could have stable graft
function while retaining a surprisingly complete ability to mount an
immune defense against infections. Consequently, the patients were
able to leave the protective “bubble” of quarantined hospital rooms,
and return to an unrestricted environment.
The term “tolerance” to describe this privileged state was strongly
criticized at the time. However, it proved to be the 
 
bon mot.
 
 Nine
patients treated in Denver during 1962–63 had function of their kid-
ney grafts for the ensuing four decades. Seven of the nine eventually
stopped all immune suppression and remained drug-free for the peri-
ods shown in Figure 8 by the shaded portion of the horizontal bars (as
long as thirty-eight years). One of the patients was murdered in a love
triangle after thirty-six years of drug freedom, and had a normal kidney
at autopsy. The remaining eight are the longest surviving kidney recipients
in the world, all but one with normal kidney function (22).
The current world’s champion was thirty-eight years old when he
received a kidney from his younger sister. Eight years later, his photo-
Figure 7. Two empirical observations in 1962–63 that made organ transplan-
tation clinically practical. First, rejection is a highly reversible immune response,
rather than being inexorable as previously thought. Second, the amount of immuno-
suppression necessary to maintain an allograft relative to that required at the
outset frequently diminishes with time. This was attributed to “organ-induced
tolerance,” a conclusion that was highly controversial for many years.
 organ transplantation
 
235
 
graph was projected at the 1970 Rhoads symposium (Fig. 9, upper).
Now, almost eighty years old (Fig. 9, lower), he still has completely
normal kidney graft function, and has been off all antirejection medi-
cation for more than a dozen years.
 
The Practical Triumph of Organ Transplantation
 
The treatment strategy developed by trial and error for kidney recipi-
ents proved to be generalizable for the transplantation of other organs.
In July 1967, the first successes with liver transplantation were ob-
tained in Denver (7) under immunosuppression with azathioprine and
prednisone, to which a third agent, antilymphocyte globulin (ALG)
was added (23). Differing from the pioneer kidney recipients only in
their much greater numbers, many of the early liver recipients were
able to stop their antirejection drugs (24). Now, after more than a third
of a century, the woman shown in Figure 10 is the longest surviving
liver recipient in the world.
By the early 1970s, the feasibility of transplantation of the liver,
Figure 8. Current status of nine (19 percent) of the forty-six live donor kidney
recipients treated at the University of Colorado over an eighteen-month period
beginning in the autumn of 1962. The shaded portion of the horizontal bars
depicts the time off immunosuppression. Four decades later, kidney function was
normal in all but one of the nine patients. CR  serum creatinine (a measure of
kidney function). *Murdered: kidney graft normal at autopsy. From ref. 22, by
permission of the Journal of the American College of Surgeons 2002;195:587–610.
 236
 
thomas e. starzl
Figure 9. The world’s longest 
surviving recipient of a kidney 
allograft. Top: slide projected at 
the Rhoads symposium of 1970, 
almost eight years after transplan-
tation. Bottom: recent photograph 
a third of a century later.
Figure 10. The world’s longest 
surviving liver recipient with her 
husband, a third of a century after 
transplantation at the age of three
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heart, and pancreas had been established unequivocally. The death rate
and morbidity remained so high, however, even with cadaver kidney
transplantation, that the future seemed truly bright only for live donor
renal transplantation from blood relatives. A frustrating decade passed
before more potent drugs became available to replace azathioprine:
cyclosporine in 1979–80 (25, 26) and tacrolimus in 1989–90 (27).
Then, it was possible for the first time to represent transplantation
of the liver (Fig. 11) (28, 29) and other cadaveric organs as a reason-
ably predictable service. By the end of the twentieth century, transplan-
tation of all of the vital organs had become part of the medical
armamentarium in almost every developed country in the world.
But the triumph was bittersweet. The daily antirejection treatment
continued to pose risks from infections and from malignant tumors
that are normally kept under control by the immune system. In addi-
tion, none of the drugs was free of toxic side effects, some of which
could ruin the transplanted organs they were designed to protect.
There were other concerns. It had been anticipated that reduction of
the incidence of acute rejection to near zero would result in a larger
number of drug-free patients such as those that had been seen in the
pioneer era. But tolerant recipients were almost never seen again. In
addition, chronic rejection now emerged as the most intractable prob-
lem in transplantation.
 
An Epiphany
 
It was obvious that further progress in transplantation would require
elucidation of the enigmatic mechanisms of both organ and bone
Figure 11. Stepwise improvements in patient survival after liver replacement.
These were associated with the advent of increasingly potent immunosuppressive
drugs. AZA  azathioprine; CYA  cyclosporine; FK  tacrolimus.
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marrow cell engraftment, rather than the development of ever more
potent immunosuppression. Was it possible, as I had suspected since the
1960s (30), that successful organ and bone marrow transplantation were
merely variations on the same theme? If so, organ engraftment was by
definition a state of partial tolerance, and there should be surviving donor
leukocytes in the tissues or blood of the successfully treated organ recipient.
What could be the source of the donor cells? It had long been
known that the “passenger leukocytes” of bone marrow origin (Fig. 2,
left) disappear from successfully transplanted organs (Fig. 2, right). It
had been thought that these cells were selectively destroyed by the host
immune response with selective preservation of the organs’ specialized
cells (e.g., those that excrete urine). Instead, we now postulated that
the passenger leukocytes migrated into the recipient, and that organ
transplantation could, in fact, be the unrecognized equivalent of a
small bone marrow cell infusion. To test this hypothesis, bits of tissue
were obtained in 1992 from various locations in recipients who had
borne functioning kidney, liver, and other kinds of organ grafts for as
long as thirty years (in Fig. 12, a liver).
With microscopic studies and with corroborating DNA analyses,
the presence of small numbers of the donor cells was demonstrated in
Figure 12. Host sites sampled in studies in 1992 of the longest surviving
kidney and liver recipients in the world. Donor leukocytes were looked for in host
blood, skin, and lymph nodes as well as in the allograft (here liver) of all patients,
and in selected cases, biopsies also were taken from the heart, intestine, other
organs, or bone marrow. The concepts depicted in Figures 13 and 14 were
deduced from the finding of low-level donor leukocyte chimerism in all patients,
and confirmed in a series of controlled animal experiments.
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Figure 13. Initial preferential migration of passenger leukocytes from organ
allografts (here a liver) to host lymphoid organs (left), where they induce a donor-
specific immune response. After about thirty days, many of the surviving cells
move on to non-lymphoid sites (right).
 
all organ recipients studied (24, 31). A grand design could now be
pieced together, whose very simplicity had cloaked its existence and
delayed its discovery. Rather than resulting from a one-way immune
reaction (Fig. 3, top), the outcome after organ transplantation, whether
rejection or engraftment, was the product of two immune responses
that begin within minutes after organ transplantation as myriads of the
passenger leukocytes begin to leave the graft for peripheral locations in
the patient (Fig. 13).
The resulting confrontation of the donor and recipient immune
cells was a classical David versus Goliath mismatch, in which the role
of David was played by the less numerous leukocytes of the organ. In
addition to inducing an attack from the recipient immune system (the
Goliath), these donor leukocytes mounted a counterattack (i.e., a graft
versus host response). The responses, each to the other, of the aroused
and multiplying donor and recipient leukocytes (Fig. 14, upper) could
result in their mutual exhaustion and disappearance. The technical
term for the process is “reciprocal clonal exhaustion-deletion.”
Reciprocal clonal exhaustion-deletion was, in fact, the seminal
mechanism of organ engraftment and of acquired tolerance. Although
outnumbered many times by the leukocytes of the recipient immune
system, residual donor cells could escape destruction by migrating to
inaccessible areas in the recipient body, where they were sheltered from
 240
 
thomas e. starzl
Figure 14. Current definition of allograft acceptance in terms of double and
mutually canceling immune reactions (compare with the historical view shown in
Fig. 3). The dominant reaction usually is host versus graft (HVG) after organ
transplantation (top), and most commonly graft versus host (GVH) after bone
marrow transplantation (bottom). After both kinds of transplantation, however,
the effective opposition to and modulation of the stronger responses by the
minority cell population are the key to engraftment.
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immune injury. From these privileged locations, the residual donor cells
may return to the main circulation and sustain the clonal exhaustion-
deletion induced at the outset (32, 33).
In the mirror-image scenario, successful bone marrow transplanta-
tion did 
 
not
 
 imply complete replacement of the cellular immune sys-
tem as had previously been thought (Fig. 3, lower). A small residual
population of recipient immune cells could always be found in bone
marrow recipients who ostensibly had complete donor leukocyte chi-
merism (Fig. 14, lower) (34). The double immune reaction common to
both organ and bone marrow transplantation differed primarily in the
relative magnitude of the host versus graft (the rejection) response (upright
curves in Fig. 15) and the graft versus host response (the inverted curves).
 
The Facilitation of Tolerance Mechanisms
 
In most organ centers today, heavy multidrug immunosuppression is
begun at the time of transplantation, and decreased to maintenance levels
over many succeeding weeks or months. The objective has been to
reduce the antigraft immune response as much as possible, with the
assumption that this will minimize early graft loss and ultimately result
in a better long-term course. Now, we realized that the immune response
that led to rejection was also the first stage in the development of toler-
ance, and that this could be inadvertently undermined by the stan-
dard policy of heavy early post-transplant immunosuppression.
Figure 15. Contemporaneous HVG (upright curves) and GVH (inverted curves)
responses following transplantation. In contrast to the usually dominant HVG
reaction of organ transplantation, the GVH reaction usually is dominant after
bone marrow cell transplantation to the irradiated or otherwise immunodepressed
recipient. Therapeutic failure with either type of transplantation implies the
inability to control one, the other, or both of the contemporaneous responses with
a protective umbrella of immunosuppression. From ref. 33, by permission of the
New England Journal of Medicine 1998;339:1905–13.
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In collaboration with Rolf Zinkernagel of Zurich (Fig. 16), an
alternative strategy was developed, the purpose of which was to lower
the donor-specific immune response into a more deletable range (35).
This involved two stages. First, the cellular immune response of the
recipient was weakened in advance of transplantation by the adminis-
tration of antilymphocyte globulin (the pretreatment principle). The
enfeebled immune response was then further reduced after transplanta-
tion with just enough antirejection treatment to prevent irreversible
destructive immunity, but not so much that the processes of immune
activation and exhaustion-deletion were eliminated (the principle of min-
imal post-transplant immunosuppression).
These simple therapeutic principles were then applied in nearly
Figure 16. Rolf Zinkernagel (1944– ). Swiss physician-immunologist whose
discovery (with Peter Doherty) of the mechanisms of the adaptive immune response
to non-cytopathic microorganisms earned the Nobel Prize in 1996. The collabora-
tion with Zinkernagel between 1997 and 2001 placed the immunology of trans-
plantation, infection, oncology, and self/non-self discrimination on common ground
(33), and resulted in the development of better treatment strategies for transplant
recipients (35).
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seven hundred cases of kidney, liver, intestine, pancreas, and lung
transplantation. The first eighty-two of these patients were reported in
the 3 May 2003 issue of the journal Lancet (36). The most important
conclusion was that major improvements in transplantation are readily
achievable with this strategy, including relief of recipients from much
of the burden of chronic antirejection therapy.
Xenotransplantation
The same treatment principles are expected to apply for the transplan-
tation of animal organs into humans (xenotransplantation). In July
2002, cloned transgenic pigs were produced in which the principal
gene that has precluded xenotransplantation was deleted (37). These
unique animals are ready to have their organs tested by transplantation
to non-human primates.
Figure 17. Disseminated pig leukocytes throughout the body of a human
recipient of a porcine liver xenograft. This outcome is expected if transgenic pig
organs are successfully transplanted to humans (see text).
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It is virtually certain that more genetic modifications will be
needed. But it is equally clear that when xenotransplantation comes to
the clinic, the mechanisms and rules of xenoengraftment will be the
same as those of human-to-human transplantation. The crucial migra-
tory cells that are at the heart of engraftment and acquired tolerance
will, of course, be those of the pig (Fig. 17).
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